New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
News
Servier Affirms Commitment to Cancer by Announcing the Opening of a Global R&D Center and Expanded Offices in Boston’s Seaport
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Servier Joins Everest Climb to Fight Cancer Benefitting Fred Hutchinson Cancer Research Center
Servier Submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib tablets) for Patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline